Xentuzumab
- CAS No.
- 1417158-65-6
- Chemical Name:
- Xentuzumab
- Synonyms
- BI 836845;Xentuzumab;Xentuzumab (anti-IGF1);Research Grade Xentuzumab
- CBNumber:
- CB28080967
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | X86Z1O656G |
| NCI Drug Dictionary | xentuzumab |
Xentuzumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620967 | Xentuzumab 99.71% | 1417158-65-6 | 1mg | $455 | 2026-06-04 | Buy |
| ChemScene | CS-0620967 | Xentuzumab 99.71% | 1417158-65-6 | 5mg | $1181 | 2026-06-04 | Buy |
| ChemScene | CS-0620967 | Xentuzumab 99.71% | 1417158-65-6 | 10mg | $1890 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1980648 | Xentuzumab Antibody 95.21% | 1417158-65-6 | 1mg | $390 | 2026-05-06 | Buy |
| Biorbyt Ltd | orb1980648 | Xentuzumab Antibody 95.21% | 1417158-65-6 | 5mg | $930 | 2026-05-06 | Buy |
Xentuzumab Chemical Properties, Uses, Production
Uses
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation[1].
in vivo
Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice[1].
| Animal Model: | Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1] |
| Dosage: | 200 mg/kg |
| Administration: | Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose |
| Result: | Resulted in significant reductions in tumor volume. |
References
[1] Weyer-Czernilofsky U, et al. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. DOI:10.1158/1535-7163.MCT-19-0378
Xentuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Xentuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
View Latest Price from Xentuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Xentuzumab
1417158-65-6
|
$347.00-1450.00 | 95.21% | 10g | TargetMol Chemicals Inc. |
-
- Xentuzumab
1417158-65-6
- $347.00-1450.00
- 95.21%
- TargetMol Chemicals Inc.
